-
Table 1 shows the patient demographics and baseline characteristics. Ninety-one patients with COPD were divided into Group 1 (n = 27) and Group N (n = 64) according to their O2Pmax value. No significant differences in age, sex, body height, body mass index, smoking history, comorbidities, or medications were observed between the two groups. However, significant differences in body weight and classification of the airflow limitation were detected between the two groups (P < 0.05). The airflow limitation was more severe in Group 1 than in Group N.
Table 1. Baseline characteristics of Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1 (n = 27) Group N (n = 64) All (n = 91) P-value Demographic Age (years) 65.1 ± 7.6 64.4 ± 7.3 64.6 ± 7.4 0.682 Male/Female (n) 23/4 52/12 75/16 0.652 Height (cm) 169.5 ± 5.4 167.4 ± 6.9 168.0 ± 6.5 0.167 Weight (kg) 73.9 ± 13.3 66.7 ± 9.3 68.9 ± 11.0 0.015 BMI (kg/m2) 24.8 ± 3.6 23.8 ± 3.1 24.1 ± 3.3 0.160 Smoking (n) 0.292 Non-smoker 4 (15%) 6 (9%) 10 (11%) Current smoker 20 (74%) 42 (66%) 62 (68%) Ex-smoker 3 (11%) 16 (25%) 19 (21%) GOLD (n) n (27) n (64) 0.014 I 1 (4%) 8 (13%) 9 (10%) II 14 (52%) 43 (67%) 57 (63%) III 9 (33%) 13 (20%) 22 (24%) IV 3 (11%) 0 (0%) 3 (3%) Comorbidities (n) n (22) n (53) 0.398 Hypertension 8 28 36 CHD 4 6 10 Type 2 diabetes 9 14 23 Hypercholesterolemia 1 5 6 Medications for COPD (n) n (27) n (64) 0.716 None 16 37 53 LABA 1 2 LAMA 1 7 LABA + LAMA 0 1 LABA + ICS 2 7 LABA + LAMA + ICS 7 10 Medications for CVD (n) n (13) n (45) 0.680 Beta-blockers 3 14 Aspirin 1 6 ACEI 1 1 CCB 3 12 ARBs 3 4 Statin 2 8 Note. Data are presented as mean ± standard deviation or numbers (percentage). All demographic data except sex were compared using the t-test. Other data were compared using the chi-square test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; CHD, coronary heart disease; LABA, long-acting beta 2 agonist; LAMA, long-acting antimuscarinic antagonist; ICS, inhaled corticosteroid; CVD, cardiovascular disease; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; ARB, angiotensin receptor blocker. -
Table 2 shows the static lung function parameters. Patients with a lower O2Pmax had lower FVC%, VC%, FEV1%, and FEV1/FVC% values (P < 0.05).
Table 2. Differences in the static lung function test parameters between Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1
(n = 27)Group N
(n = 64)All
(n = 91)P-value FVC (% predicted) 75.00 ± 16.67 86.80 ± 16.57 83.30 ± 1.82 0.003 VC (% predicted) 72.55 ± 16.34 84.45 ± 16.29 80.92 ± 1.79 0.003 FEV1 (% predicted) 51.49 ± 20.33 63.79 ± 16.15 60.14 ± 1.92 0.003 FEV1/FVC (%) 52.25 ± 13.07 58.34 ± 10.46 56.53 ± 1.21 0.038 RV/ TLC (%) 0.57 ± 0.11 0.55 ± 0.17 0.56 ± 0.02 0.618 PEF (% predicted) 60.81 ± 24.02 69.80 ± 21.70 67.14 ± 2.37 0.084 MMEF75/25(% predicted) 20.03 ± 11.40 24.01 ± 11.00 22.83 ± 1.17 0.121 TLCO/VA (% predicted) 73.41 ± 26.16 81.11 ± 21.56 78.83 ± 2.43 0.148 Note. Data are presented as mean ± standard deviation. Data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: FVC, forced vital capacity; VC, vital capacity; FEV1, forced expiratory volume in 1 s; RV, residual volume; TLC, total lung capacity; PEF, peak expiratory flow; MMEF75/25, maximal mid-expiratory flow rate 75/25; TLCO/VA, transfer factor of the lungs for carbon monoxide/alveolar volume. -
Table 3 shows the CPET variables. AT, WR, V̇O2, V̇O2/kg, HR, systolic BP, diastolic BP, V̇E, BR, and EqCO2 were measured at the AT and maximum exercise during CPET. HRR1 was calculated after the exercise. Significant differences in AT, WR%, V̇O2%, V̇O2/kg%, V̇E%, EqCO2AT, and EqCO2max were observed between the two groups (P < 0.05). Among these variables, EqCO2AT and EqCO2max were higher in patients with impaired O2Pmax, whereas the other variables were lower. Significant differences were also detected in HRR1 (P < 0.05), which was regarded as a circulatory parameter.
Table 3. Differences in the CPET parameters between Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1 (n = 27) Group N (n = 64) All (n = 91) P-value AT (%) 37.92 ± 9.34 54.51 ± 11.85 49.59 ± 13.47 < 0.001 WR (% predicted) 57.67 ± 15.07 90.84 ± 22.92 81.00 ± 25.80 < 0.001 V̇O2 (% predicted) 55.37 ± 8.21 77.86 ± 13.37 71.19 ± 15.85 < 0.001 V̇O2/kg (% predicted) 54.78 ± 8.37 77.63 ± 12.18 70.85 ± 15.31 < 0.001 HRAT (beats/min) 106.70 ± 12.14 106.83 ± 14.06 106.79 ± 13.45 0.968 HRmax (beats/min) 130.59 ± 16.70 130.86 ± 18.80 130.78 ± 13.11 0.949 SBPAT (mmHg) 140.96 ± 24.68 137.53 ± 23.47 138.55 ± 23.75 0.542 SBPmax (mmHg) 167.63 ± 23.07 161.31 ± 31.08 163.19 ± 28.95 0.345 DBPAT (mmHg) 81.19 ± 12.57 83.77 ± 18.98 83.00 ± 17.30 0.519 DBPmax (mmHg) 90.41 ± 17.47 94.94 ± 29.50 93.58 ± 26.45 0.460 V̇E (% predicted) 47.26 ± 11.73 62.83 ± 14.02 58.21 ± 15.12 < 0.001 BRAT (mL/min) 42.56 ± 18.74 50.94 ± 14.03 48.45 ± 15.94 0.043 BR (% predicted) 71.11 ± 70.12 73.14 ± 64.31 72.54 ± 65.70 0.894 EqCO2AT 35.65 ± 6.05 32.33 ± 4.94 33.31 ± 5.48 0.007 EqCO2max 34.10 ± 6.93 30.93 ± 5.86 31.87 ± 6.32 0.028 HRR1 (beats/min) 14.78 ± 7.66 19.28 ± 9.66 17.95 ± 9.30 0.034 Note. Data are presented as mean ± standard deviation. Data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: AT, anaerobic threshold; WR, work rate; V̇O2, oxygen uptake; V̇O2/kg, oxygen uptake per kilogram; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; V̇E, minute ventilation; BR, breathing reserve; EqCO2, ventilatory equivalent for carbon dioxide; HRR1, heart rate recovery after 1 min of rest. -
Table 4 shows the CAT, mMRC, Borg CR10 scale, and SGRQ scores. The Borg CR10 scale, SGRQ total, SGRQ symptom, and SGRQ activity scores were significantly higher in Group 1 than those in Group N (P < 0.05).
Table 4. Differences in the dyspnea scores between Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1 (n = 27) Group N (n = 64) All (n = 91) P-value CAT (points) 12.50 ± 5.32 9.79 ± 4.01 10.79 ± 4.66 0.084 mMRC (points) 1.71 ± 0.73 1.29 ± 0.76 1.45 ± 0.76 0.099 Borg CR10 (points) 2.64 ± 1.21 1.56 ± 1.45 1.96 ± 1.45 0.025 SGRQ, total (points) 41.78 ± 12.46 25.61 ± 17.15 33.31 ± 16.89 0.024 SGRQ, symptom (points) 54.30 ± 19.34 29.47 ± 17.51 41.29 ± 21.98 0.006 SGRQ, activity (points) 55.89 ± 11.11 35.65 ± 25.67 45.29 ± 22.19 0.032 SGRQ, impact (points) 33.57 ± 15.99 19.66 ± 15.12 26.28 ± 16.73 0.055 Note. Data are presented as mean ± standard deviation. Data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. The CAT, mMRC, and SGRQ were evaluated before CPET; the Borg CR10 was evaluated immediately after CPET. Abbreviations: CAT, COPD Assessment Test; mMRC, modified Medical Research Council scale; Borg CR10, Borg’s 10-point category-ratio scale; SGRQ, St. George’s Respiratory Questionnaire. -
Figure 1 shows the correlation coefficients between O2Pmax and FEV1/FVC%, FEV1%, and FVC%, which were regarded as lung ventilation function variables. O2Pmax was slightly but significantly correlated with FEV1/FVC% (r = 0.207, P < 0.05), FEV1% (r = 0.267, P < 0.05), and FVC% (r = 0.288, P < 0.01).
-
Figure 2 shows the correlation coefficients between O2Pmax and the CPET variables. O2Pmax was positively correlated with AT (r = 0.623, P < 0.001), WR% (r = 0.613, P < 0.001), V̇O2max% (r = 0.681, P < 0.001), V̇O2/kgmax% (r = 0.707, P < 0.001), and V̇Emax% (r = 0.399, P < 0.001), but negatively correlated with EqCO2AT (r = −0.302, P < 0.01) and EqCO2max (r = −0.214, P < 0.05).
-
Table 5 shows that FVC%, FEV1%, O2Pmax%, WRmax, and V̇O2max were significantly lower in the AE2 group than in the AE1 group (P < 0.05).
Table 5. Characteristics, pulmonary function, and CPET data of the patients with COPD grouped in acute exacerbation
Item AE1 group (n = 30) AE2 group (n = 27) P-value Age (Years) 63.73 ± 8.09 64.30 ± 6.92 0.780 Weight (kg) 69.00 ± 8.60 70.48 ± 13.83 0.625 Smoke (numbers) 27.50 (40.75) 15.00 (30.00) 0.257 Male/Female (n) 25/5 23/4 0.261 FVC (% predicted) 87.08 ± 16.94 76.84 ± 13.88 0.016 FEV1 (% predicted) 63.52 ± 16.25 51.52 ± 17.78 0.010 FEV1/FVC (%) 57.44 ± 9.26 52.12 ± 13.13 0.080 O2Pmax (% predicted) 93.23 ± 13.10 79.93 ± 15.41 0.001 WRmax (watts) 101.70 ± 21.63 80.48 ± 24.66 0.001 V̇O2max (mL/min) 1350.23 ± 230.16 1141.15 ± 279.00 0.003 Note. Data are presented as mean ± standard deviation, median (IQR), or number. Sex was compared using the chi-square test, smoke was compared using the Mann-Whitney test, and the remaining data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: AE, acute exacerbation; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; O2P, oxygen pulse; WR, work rate; V̇O2, oxygen uptake. -
The univariate logistic regression confirmed that O2Pmax was an independent predictor of AECOPD [odds ratio (OR), 1.068; 95% CI, 1.023–1.116; P = 0.003]. Five variables (FVC%, FEV1%, O2Pmax, WRmax, and V̇O2max) were used to build a logistic regression model to predict AECOPD in a multivariate analysis (Tables 6-7). Only O2Pmax was a predictor of AECOPD (OR = 1.062, 95% CI = 1.012–1.114, P = 0.015). ROC curve analysis was applied to categorize the optimal cut-off value of O2Pmax for exacerbation (Figure 3). The AUC was 0.739 (95% CI = 0.609–0.869, P = 0.002). The cut-off value was 89.5%, with a sensitivity of 63.30% and a specificity of 77.80%.
Table 6. Multivariate logistic regression analysis of lung function and the CPET data in patients with AECOPD
Item β P-value OR 95% CI FVC (% predicted) 0.012 0.724 1.012 (0.949–1.078) FEV1 (% predicted) 0.004 0.898 1.004 (0.946–1.065) O2Pmax (% predicted) 0.060 0.015 1.062 (1.012–1.114) WRmax (watts) 0.052 0.215 1.053 (0.970–1.143) V̇O2max (mL/min) –0.002 0.608 0.998 (0.992–1.005) Note. Only O2Pmax had a predictive effect for AECOPD (OR = 1.062, 95% CI = 1.012–1.114, P = 0.015). Bold numbers indicate a significant difference (P < 0.05). Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; O2P, oxygen pulse; WR, work rate; V̇O2, oxygen uptake; OR, odds ratio; CI, confidence interval. Table 7. Univariate logistic regression analysis of O2Pmax in patients with AECOPD
Item β P-value OR 95% CI O2Pmax (% predicted) 0.066 0.003 1.068 (1.023–1.116) Note. O2Pmax was a predictor of AECOPD (OR = 1,068, 95% CI = 1.023–1.116, P = 0.003). The bold number indicates a significant difference (P < 0.05) between the two groups. Abbreviations: OR, odds ratio; CI, confidence interval.
doi: 10.3967/bes2022.107
Effect of Maximal Oxygen Pulse on Patients with Chronic Obstructive Pulmonary Disease
-
Abstract:
Objective This study evaluated the effect of maximal oxygen pulse (O2Pmax) on patients with chronic obstructive pulmonary disease (COPD) and confirmed the predictive effect on acute exacerbations of COPD (AECOPD). Methods This retrospective study included 91 participants who underwent cardiopulmonary exercise testing (CPET), lung function testing, a dyspnea scale assessment, and a 3-year follow-up. The participants were divided into two groups according to the O2Pmax value. Exercise capacity, ventilatory conditions, gas exchange efficiency, and dyspnea symptoms were compared, and the correlations between O2Pmax and these indices were evaluated. The ability of O2Pmax to predict AECOPD was examined. Results Exercise capacity, ventilatory conditions, and gas exchange efficiency were lower, and dyspnea symptom scores were higher in the impaired O2Pmax group (P < 0.05). O2Pmax was positively correlated with forced vital capacity (FVC)%, forced expiratory volume in 1 sec (FEV1)%, FEV1/FVC%, anaerobic threshold (AT), work rate (WR)%, aximal oxygen uptake (V̇O2max)%, V̇O2/kgmax, V̇O2/kgmax%, WRAT, WRmax, V̇O2AT, V̇O2max, and V̇Emax, and was negatively correlated with EqCO2AT, and EqCO2max (P < 0.05). Most importantly, O2Pmax could be used to predict AECOPD, and the best cut-off value was 89.5% (area under the curve, 0.739; 95% CI, 0.609–0.869). Conclusion O2Pmax reflected exercise capacity, ventilation capacity, gas exchange capacity, and dyspnea symptoms in patients with COPD and may be an independent predictor of AECOPD. -
Key words:
- Oxygen pulse /
- Chronic obstructive pulmonary disease /
- Cardiopulmonary exercise test /
- Acute exacerbation
The authors declare that they have no competing interests.
注释:1) AUTHORS’ CONTRIBUTIONS: 2) COMPETING INTERESTS: -
Table 1. Baseline characteristics of Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1 (n = 27) Group N (n = 64) All (n = 91) P-value Demographic Age (years) 65.1 ± 7.6 64.4 ± 7.3 64.6 ± 7.4 0.682 Male/Female (n) 23/4 52/12 75/16 0.652 Height (cm) 169.5 ± 5.4 167.4 ± 6.9 168.0 ± 6.5 0.167 Weight (kg) 73.9 ± 13.3 66.7 ± 9.3 68.9 ± 11.0 0.015 BMI (kg/m2) 24.8 ± 3.6 23.8 ± 3.1 24.1 ± 3.3 0.160 Smoking (n) 0.292 Non-smoker 4 (15%) 6 (9%) 10 (11%) Current smoker 20 (74%) 42 (66%) 62 (68%) Ex-smoker 3 (11%) 16 (25%) 19 (21%) GOLD (n) n (27) n (64) 0.014 I 1 (4%) 8 (13%) 9 (10%) II 14 (52%) 43 (67%) 57 (63%) III 9 (33%) 13 (20%) 22 (24%) IV 3 (11%) 0 (0%) 3 (3%) Comorbidities (n) n (22) n (53) 0.398 Hypertension 8 28 36 CHD 4 6 10 Type 2 diabetes 9 14 23 Hypercholesterolemia 1 5 6 Medications for COPD (n) n (27) n (64) 0.716 None 16 37 53 LABA 1 2 LAMA 1 7 LABA + LAMA 0 1 LABA + ICS 2 7 LABA + LAMA + ICS 7 10 Medications for CVD (n) n (13) n (45) 0.680 Beta-blockers 3 14 Aspirin 1 6 ACEI 1 1 CCB 3 12 ARBs 3 4 Statin 2 8 Note. Data are presented as mean ± standard deviation or numbers (percentage). All demographic data except sex were compared using the t-test. Other data were compared using the chi-square test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; CHD, coronary heart disease; LABA, long-acting beta 2 agonist; LAMA, long-acting antimuscarinic antagonist; ICS, inhaled corticosteroid; CVD, cardiovascular disease; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; ARB, angiotensin receptor blocker. Table 2. Differences in the static lung function test parameters between Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1
(n = 27)Group N
(n = 64)All
(n = 91)P-value FVC (% predicted) 75.00 ± 16.67 86.80 ± 16.57 83.30 ± 1.82 0.003 VC (% predicted) 72.55 ± 16.34 84.45 ± 16.29 80.92 ± 1.79 0.003 FEV1 (% predicted) 51.49 ± 20.33 63.79 ± 16.15 60.14 ± 1.92 0.003 FEV1/FVC (%) 52.25 ± 13.07 58.34 ± 10.46 56.53 ± 1.21 0.038 RV/ TLC (%) 0.57 ± 0.11 0.55 ± 0.17 0.56 ± 0.02 0.618 PEF (% predicted) 60.81 ± 24.02 69.80 ± 21.70 67.14 ± 2.37 0.084 MMEF75/25(% predicted) 20.03 ± 11.40 24.01 ± 11.00 22.83 ± 1.17 0.121 TLCO/VA (% predicted) 73.41 ± 26.16 81.11 ± 21.56 78.83 ± 2.43 0.148 Note. Data are presented as mean ± standard deviation. Data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: FVC, forced vital capacity; VC, vital capacity; FEV1, forced expiratory volume in 1 s; RV, residual volume; TLC, total lung capacity; PEF, peak expiratory flow; MMEF75/25, maximal mid-expiratory flow rate 75/25; TLCO/VA, transfer factor of the lungs for carbon monoxide/alveolar volume. Table 3. Differences in the CPET parameters between Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1 (n = 27) Group N (n = 64) All (n = 91) P-value AT (%) 37.92 ± 9.34 54.51 ± 11.85 49.59 ± 13.47 < 0.001 WR (% predicted) 57.67 ± 15.07 90.84 ± 22.92 81.00 ± 25.80 < 0.001 V̇O2 (% predicted) 55.37 ± 8.21 77.86 ± 13.37 71.19 ± 15.85 < 0.001 V̇O2/kg (% predicted) 54.78 ± 8.37 77.63 ± 12.18 70.85 ± 15.31 < 0.001 HRAT (beats/min) 106.70 ± 12.14 106.83 ± 14.06 106.79 ± 13.45 0.968 HRmax (beats/min) 130.59 ± 16.70 130.86 ± 18.80 130.78 ± 13.11 0.949 SBPAT (mmHg) 140.96 ± 24.68 137.53 ± 23.47 138.55 ± 23.75 0.542 SBPmax (mmHg) 167.63 ± 23.07 161.31 ± 31.08 163.19 ± 28.95 0.345 DBPAT (mmHg) 81.19 ± 12.57 83.77 ± 18.98 83.00 ± 17.30 0.519 DBPmax (mmHg) 90.41 ± 17.47 94.94 ± 29.50 93.58 ± 26.45 0.460 V̇E (% predicted) 47.26 ± 11.73 62.83 ± 14.02 58.21 ± 15.12 < 0.001 BRAT (mL/min) 42.56 ± 18.74 50.94 ± 14.03 48.45 ± 15.94 0.043 BR (% predicted) 71.11 ± 70.12 73.14 ± 64.31 72.54 ± 65.70 0.894 EqCO2AT 35.65 ± 6.05 32.33 ± 4.94 33.31 ± 5.48 0.007 EqCO2max 34.10 ± 6.93 30.93 ± 5.86 31.87 ± 6.32 0.028 HRR1 (beats/min) 14.78 ± 7.66 19.28 ± 9.66 17.95 ± 9.30 0.034 Note. Data are presented as mean ± standard deviation. Data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: AT, anaerobic threshold; WR, work rate; V̇O2, oxygen uptake; V̇O2/kg, oxygen uptake per kilogram; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; V̇E, minute ventilation; BR, breathing reserve; EqCO2, ventilatory equivalent for carbon dioxide; HRR1, heart rate recovery after 1 min of rest. Table 4. Differences in the dyspnea scores between Group 1 (O2Pmax < 80% predicted) and Group N (O2Pmax ≥ 80% predicted)
Item Group 1 (n = 27) Group N (n = 64) All (n = 91) P-value CAT (points) 12.50 ± 5.32 9.79 ± 4.01 10.79 ± 4.66 0.084 mMRC (points) 1.71 ± 0.73 1.29 ± 0.76 1.45 ± 0.76 0.099 Borg CR10 (points) 2.64 ± 1.21 1.56 ± 1.45 1.96 ± 1.45 0.025 SGRQ, total (points) 41.78 ± 12.46 25.61 ± 17.15 33.31 ± 16.89 0.024 SGRQ, symptom (points) 54.30 ± 19.34 29.47 ± 17.51 41.29 ± 21.98 0.006 SGRQ, activity (points) 55.89 ± 11.11 35.65 ± 25.67 45.29 ± 22.19 0.032 SGRQ, impact (points) 33.57 ± 15.99 19.66 ± 15.12 26.28 ± 16.73 0.055 Note. Data are presented as mean ± standard deviation. Data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. The CAT, mMRC, and SGRQ were evaluated before CPET; the Borg CR10 was evaluated immediately after CPET. Abbreviations: CAT, COPD Assessment Test; mMRC, modified Medical Research Council scale; Borg CR10, Borg’s 10-point category-ratio scale; SGRQ, St. George’s Respiratory Questionnaire. Table 5. Characteristics, pulmonary function, and CPET data of the patients with COPD grouped in acute exacerbation
Item AE1 group (n = 30) AE2 group (n = 27) P-value Age (Years) 63.73 ± 8.09 64.30 ± 6.92 0.780 Weight (kg) 69.00 ± 8.60 70.48 ± 13.83 0.625 Smoke (numbers) 27.50 (40.75) 15.00 (30.00) 0.257 Male/Female (n) 25/5 23/4 0.261 FVC (% predicted) 87.08 ± 16.94 76.84 ± 13.88 0.016 FEV1 (% predicted) 63.52 ± 16.25 51.52 ± 17.78 0.010 FEV1/FVC (%) 57.44 ± 9.26 52.12 ± 13.13 0.080 O2Pmax (% predicted) 93.23 ± 13.10 79.93 ± 15.41 0.001 WRmax (watts) 101.70 ± 21.63 80.48 ± 24.66 0.001 V̇O2max (mL/min) 1350.23 ± 230.16 1141.15 ± 279.00 0.003 Note. Data are presented as mean ± standard deviation, median (IQR), or number. Sex was compared using the chi-square test, smoke was compared using the Mann-Whitney test, and the remaining data were compared using the t-test. Bold numbers indicate a significant difference (P < 0.05) between the two groups. Abbreviations: AE, acute exacerbation; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; O2P, oxygen pulse; WR, work rate; V̇O2, oxygen uptake. Table 6. Multivariate logistic regression analysis of lung function and the CPET data in patients with AECOPD
Item β P-value OR 95% CI FVC (% predicted) 0.012 0.724 1.012 (0.949–1.078) FEV1 (% predicted) 0.004 0.898 1.004 (0.946–1.065) O2Pmax (% predicted) 0.060 0.015 1.062 (1.012–1.114) WRmax (watts) 0.052 0.215 1.053 (0.970–1.143) V̇O2max (mL/min) –0.002 0.608 0.998 (0.992–1.005) Note. Only O2Pmax had a predictive effect for AECOPD (OR = 1.062, 95% CI = 1.012–1.114, P = 0.015). Bold numbers indicate a significant difference (P < 0.05). Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; O2P, oxygen pulse; WR, work rate; V̇O2, oxygen uptake; OR, odds ratio; CI, confidence interval. Table 7. Univariate logistic regression analysis of O2Pmax in patients with AECOPD
Item β P-value OR 95% CI O2Pmax (% predicted) 0.066 0.003 1.068 (1.023–1.116) Note. O2Pmax was a predictor of AECOPD (OR = 1,068, 95% CI = 1.023–1.116, P = 0.003). The bold number indicates a significant difference (P < 0.05) between the two groups. Abbreviations: OR, odds ratio; CI, confidence interval. -
[1] Rothnie KJ, Müllerová H, Smeeth L, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care, 2018; 198, 464−71. doi: 10.1164/rccm.201710-2029OC [2] Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest, 2015; 147, 999−1007. doi: 10.1378/chest.14-0655 [3] Soriano JB, Lamprecht B, Ramírez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med, 2015; 3, 443−50. doi: 10.1016/S2213-2600(15)00157-5 [4] Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med, 2013; 1(1), 43−50. [5] Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care, 2003; 167, 544−9. doi: 10.1164/rccm.200206-583OC [6] Chuang ML, Huang SF, Su CH. Cardiovascular and respiratory dysfunction in chronic obstructive pulmonary disease complicated by impaired peripheral oxygenation. Int J Chron Obstruct Pulmon Dis, 2015; 10, 329−37. [7] Stickland MK, Neder JA, Guenette JA, et al. Using cardiopulmonary exercise testing to understand dyspnea and exercise intolerance in respiratory disease. Chest, 2022; 161, 1505−16. doi: 10.1016/j.chest.2022.01.021 [8] Oelberg DA, Kacmarek RM, Pappagianopoulos PP, et al. Ventilatory and cardiovascular responses to inspired He-O2 during exercise in chronic obstructive pulmonary disease. Am J Resp Crit Care, 1998; 158, 1876−82. doi: 10.1164/ajrccm.158.6.9802015 [9] Cortopassi F, Divo M, Pinto-Plata V, et al. Resting handgrip force and impaired cardiac function at rest and during exercise in COPD patients. Respir Med, 2011; 105, 748−54. doi: 10.1016/j.rmed.2010.12.011 [10] Miniati M, Catapano GA, Monti S, et al. Effects of emphysema on oxygen uptake during maximal exercise in COPD. Intern Emerg Med, 2013; 8, 41−7. [11] Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J, 2005; 26, 420−8. doi: 10.1183/09031936.05.00136304 [12] Barberà JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J, 1997; 10, 1285−91. doi: 10.1183/09031936.97.10061285 [13] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of obstructive pulmonary disease. 2022 report. https://goldcopd.org/ [14] Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J, 2005; 26, 319−38. doi: 10.1183/09031936.05.00034805 [15] American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med, 2003; 167, 211−77. doi: 10.1164/rccm.167.2.211 [16] Criner GJ, Belt P, Sternberg AL, et al. Effects of lung volume reduction surgery on gas exchange and breathing pattern during maximum exercise. Chest, 2009; 135, 1268−1279. doi: 10.1378/chest.08-1625 [17] Glaab T, Schmidt O, Fritsch J. Guidance to the interpretation of cardiopulmonary exercise testing. Pneumologie, 2020; 74, 88−102. doi: 10.1055/a-1069-0611 [18] Chiappa GR, Queiroga FJ, Meda E, et al. Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care, 2009; 179, 1004−10. doi: 10.1164/rccm.200811-1793OC [19] Torres-Castro R, Gimeno-Santos E, Vilaró J, et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis. Eur Respir Rev, 2021; 30, 200321. doi: 10.1183/16000617.0321-2020 [20] O'Donnell DE, Elbehairy AF, Faisal A, et al. Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing. Eur Respir Rev, 2016; 25, 333−47. doi: 10.1183/16000617.0054-2016 [21] Frazão M, Silva PE, Frazão W, et al. Dynamic hyperinflation impairs cardiac performance during exercise in COPD. J Cardiopulm Rehabil Prev, 2019; 39, 187−92. doi: 10.1097/HCR.0000000000000325 [22] Come CE, Divo MJ, San José Estépar R, et al. Lung deflation and oxygen pulse in COPD: results from the NETT randomized trial. Respir Med, 2012; 106, 109−19. doi: 10.1016/j.rmed.2011.07.012 [23] Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. New Engl J Med, 2010; 362, 217−27. doi: 10.1056/NEJMoa0808836 [24] Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J, 2008; 32, 1275−82. doi: 10.1183/09031936.00151707 [25] Park J, Lee CH, Lee YJ, et al. Longitudinal changes in lung hyperinflation in COPD. Int J Chron Obstruct Pulmon Dis, 2017; 12, 501−8. doi: 10.2147/COPD.S122909 [26] Silvestre OM, Nadruz W, Querejeta Roca G, et al. Declining lung function and cardiovascular risk: the ARIC study. J Am Coll Cardiol, 2018; 72, 1109−22. doi: 10.1016/j.jacc.2018.06.049 [27] Lacasse M, Maltais F, Poirier P, et al. Post-exercise heart rate recovery and mortality in chronic obstructive pulmonary disease. Respir Med, 2005; 99, 877−86. doi: 10.1016/j.rmed.2004.11.012 [28] Cole CR, Blackstone EH, Pashkow FJ, et al. Heart-rate recovery immediately after exercise as a predictor of mortality. New Engl J Med, 1999; 341, 1351−7. doi: 10.1056/NEJM199910283411804 [29] Zhang JL, Schaeffer MR, Mitchell RA, et al. A multidimensional assessment of dyspnoea in healthy adults during exercise. Eur J Appl Physiol, 2020; 120, 2533−45. doi: 10.1007/s00421-020-04479-2 [30] Souza GF, Sarmento A, Moreira GL, et al. The glittre ADL-test differentiates COPD patients with and without self-reported functional limitation. COPD J Chron Obstruct Pulmon Dis, 2020; 17, 143−149. doi: 10.1080/15412555.2020.1716707 [31] Lan CC, Chu WH, Yang MC, et al. Benefits of pulmonary rehabilitation in patients with COPD and normal exercise capacity. Respir Care, 2013; 58, 1482−8. doi: 10.4187/respcare.02051 [32] De Oca MM, Rassulo J, Celli BR. Respiratory muscle and cardiopulmonary function during exercise in very severe COPD. Am J Respir Crit Care, 1996; 154, 1284−9. doi: 10.1164/ajrccm.154.5.8912737 [33] Murray SA, Kendall M, Boyd K, et al. Illness trajectories and palliative care. BMJ, 2005; 330, 1007−11. doi: 10.1136/bmj.330.7498.1007 [34] Hurst JR, Wedzicha JA. What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines. Thorax, 2007; 62, 198−9. doi: 10.1136/thx.2007.077883 [35] Hurst JR, Anzueto A, Vestbo J. Susceptibility to exacerbation in COPD. Lancet Respir Med, 2017; 5, e29. doi: 10.1016/S2213-2600(17)30307-7 [36] Gudmundsson G, Ulrik CS, Gislason T, et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis, 2012; 7, 571−6. [37] Wu CW, Hsieh PC, Yang MC, et al. Impact of peak oxygen pulse on patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2019; 14, 2543−2551. doi: 10.2147/COPD.S224735